Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

By F. Sirotnak, M. Zakowski, V. Miller, H. Scher, M. Kris. Clinical Cancer Research, 2000

807 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/d1a687257f1d8e618f1a0fda8ba40c7f948985f0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. (2007, methodology): “150 mg/kg/d by daily oral gavage as previously described (40).”
Molecular mechanisms of drug resistance (2005, background): “In vitro and xenograft studies have found that gefitinib enhances the cytotoxic effects of a variety of chemotherapies [216–219].”
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. (2001, background): “These include the currently approved cancer therapy, Herceptin (27, 28), and the small molecule inhibitors OSI-774 (2, 7), Iressa (29), and CI 1033 (30), which are currently in clinical trials.”
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. (2001, background): “Finally, evidence of antitumor activity of OSI-774 in patients with advanced NSCLC that had failed a platinum-based therapy was reported recently (98).”
Targeting the EGFR signaling pathway in cancer therapy (2012, background): “inhibition in vivo without an increase in the severity of coadministrated cytotoxic drugs [69,82].”
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. (2004, methodology): “This rationale is supported by data from preclinical studies in which gefitinib potentiated the efficacy of various cytotoxic drugs against a range of human solid tumor types, both in vitro and in vivo [12,13].”
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. (2004, background): “In preclinical studies, gefitinib enhanced the efficacy of cytotoxic agents against a range of human tumor xenografts, including lung cancer, regardless of EGFR expression [13,14].”